» Articles » PMID: 25767265

Evolution of the "drivers" of Translational Cancer Epidemiology: Analysis of Funded Grants and the Literature

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 2015 Mar 14
PMID 25767265
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Concurrently with a workshop sponsored by the National Cancer Institute, we identified key "drivers" for accelerating cancer epidemiology across the translational research continuum in the 21st century: emerging technologies, a multilevel approach, knowledge integration, and team science. To map the evolution of these "drivers" and translational phases (T0-T4) in the past decade, we analyzed cancer epidemiology grants funded by the National Cancer Institute and published literature for 2000, 2005, and 2010. For each year, we evaluated the aims of all new/competing grants and abstracts of randomly selected PubMed articles. Compared with grants based on a single institution, consortium-based grants were more likely to incorporate contemporary technologies (P = 0.012), engage in multilevel analyses (P = 0.010), and incorporate elements of knowledge integration (P = 0.036). Approximately 74% of analyzed grants and publications involved discovery (T0) or characterization (T1) research, suggesting a need for more translational (T2-T4) research. Our evaluation indicated limited research in 1) a multilevel approach that incorporates molecular, individual, social, and environmental determinants and 2) knowledge integration that evaluates the robustness of scientific evidence. Cancer epidemiology is at the cusp of a paradigm shift, and the field will need to accelerate the pace of translating scientific discoveries in order to impart population health benefits. While multi-institutional and technology-driven collaboration is happening, concerted efforts to incorporate other key elements are warranted for the discipline to meet future challenges.

Citing Articles

The future of translational research on alcohol use disorder.

Ray L, Grodin E, Leggio L, Bechtholt A, Becker H, Feldstein Ewing S Addict Biol. 2020; 26(2):e12903.

PMID: 32286721 PMC: 7554164. DOI: 10.1111/adb.12903.


Mapping the evolving definitions of translational research.

Fort D, Herr T, Shaw P, Gutzman K, Starren J J Clin Transl Sci. 2017; 1(1):60-66.

PMID: 28480056 PMC: 5408839. DOI: 10.1017/cts.2016.10.


Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.

Lynch J, Berse B, Dotson W, Khoury M, Coomer N, Kautter J Genet Med. 2017; 19(8):890-899.

PMID: 28125086 DOI: 10.1038/gim.2016.209.


Obesity and associated lifestyles modify the effect of glucose metabolism-related genetic variants on impaired glucose homeostasis among postmenopausal women.

Jung S, Sobel E, Papp J, Crandall C, Fu A, Zhang Z Genet Epidemiol. 2016; 40(6):520-30.

PMID: 27377425 PMC: 5560051. DOI: 10.1002/gepi.21991.

References
1.
Khoury M, Gwinn M, Dotson W, Schully S . Knowledge integration at the center of genomic medicine. Genet Med. 2012; 14(7):643-7. PMC: 4681509. DOI: 10.1038/gim.2012.43. View

2.
Ioannidis J, Schully S, Lam T, Khoury M . Knowledge integration in cancer: current landscape and future prospects. Cancer Epidemiol Biomarkers Prev. 2012; 22(1):3-10. PMC: 4697937. DOI: 10.1158/1055-9965.EPI-12-1144. View

3.
Lam T, Spitz M, Schully S, Khoury M . "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev. 2013; 22(2):181-8. PMC: 3565029. DOI: 10.1158/1055-9965.EPI-12-1262. View

4.
Khoury M, Lam T, Ioannidis J, Hartge P, Spitz M, Buring J . Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):508-16. PMC: 3625652. DOI: 10.1158/1055-9965.EPI-13-0146. View

5.
Lynch S, Rebbeck T . Bridging the gap between biologic, individual, and macroenvironmental factors in cancer: a multilevel approach. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):485-95. PMC: 3645448. DOI: 10.1158/1055-9965.EPI-13-0010. View